**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 54766

**Manuscript Type:** OPINIONREVIEW

**Tailored classification of portal vein thrombosis for liver transplantation: Focus on strategies for portal vein inflow reconstruction**

Teng F *et al.* Tailored classification of PVT for LT

Fei Teng, Ke-Yan Sun, Zhi-Ren Fu

**FeiTeng, Ke-Yan Sun, Zhi-Ren Fu,** Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Navy Medical University, Shanghai 200003, China

**Author contributions:** Teng F and Sun KY contributed equally to this paper regarding the conception and design of the study, literature review and analysis, and drafting and editing of the manuscript. Fu ZR made critical revisions and all authors approved the final version.

**Supported by** the National Natural Science Foundation of China, No. 81702923.

**Corresponding author: Zhi-Ren Fu, MPhil, Director, Professor, Surgeon,** Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Navy Medical University, 415 Fengyang Road, Huangpu District, Shanghai 200003, China.zhirenf@smmu.edu.cn

**Received:** February 17, 2020

**Revised:** March 25, 2020

**Accepted:** April 22, 2020

**Published online:** June 7, 2020

**Abstract**

Portal vein thrombosis (PVT) is currently not considered a contraindication for liver transplantation (LT), but diffuse or complicated PVT remains a major surgical challenge. Here, we review the prevalence, natural course and current grading systems of PVT and propose a tailored classification of PVT in the setting of LT. PVT in liver transplant recipients is classified into three types, corresponding to three portal reconstruction strategies: anatomical, physiological and non-physiological. Type I PVT can be removed via low dissection of the portal vein (PV) or thrombectomy; porto-portal anastomosis is then performed with or without an interposed vascular graft. Physiological reconstruction used for type II PVT includes vascular interposition between mesenteric veins and PV, collateral-PV and splenic vein-PV anastomosis. Non-physiological reconstruction used for type III PVT includes cavoportal hemitransposition, renoportal anastomosis, portal vein arterialization and multivisceral transplantation. All portal reconstruction techniques were reviewed. This tailored classification system stratifies PVT patients by surgical complexity, risk of postoperative complications and long-term survival. We advocate using the tailored classification for PVT grading before LT, which will urge transplant surgeons to make a better preoperative planning and pay more attention to all potential strategies for portal reconstruction. Further verification in a large-sample cohort study is needed.

**Key words:** Portal vein thrombosis; Liver transplantation; Portal reconstruction; Grading; Anatomical; Physiological; Non-physiological

**Citation:** Teng F, Sun KY, Fu ZR. Tailored classification of portal vein thrombosis for liver transplantation: Focus on strategies for portal vein inflow reconstruction.*World J Gastroenterol* 2020; Teng F, Sun KY, Fu ZR. Tailored classification of portal vein thrombosis for liver transplantation: Focus on strategies for portal vein inflow reconstruction.*World J Gastroenterol* 2020; 26(21): 2691-2701

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i21/2691.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i21.2691

**Core tip:** In the tailored classification for liver transplantation, portal vein thrombosis (PVT) is divided into types I, II and III according to the vascular sources used for portal reconstruction. The proposed algorithm for the tailored PVT classification and PV reconstruction strategy contributes to stratification of PVT patients by surgical complexity, risk of postoperative complications and long-term survival.

**INTRODUCTION**

Portal vein thrombosis (PVT) generally refers to complete or partial obstruction of blood flow in the portal vein and/or its main branches due to a non-neoplastic thrombus. A malignant embolus is termed tumurous invasion of the portal vein, constituting another clinical entity with different pathogenesis, treatment and prognosis[[1](#_ENREF_1)]. PVT has long been considered a contraindication for liver transplantation (LT), as adequate portal inflow cannot always be ensured. However, when PVT is removed *en bloc* with the liver or through thrombectomy, a routine porto-portal anastomosis can still be performed. For some complex PVTs, alternative approaches can redirect the portal venous flow into the graft to achieve physiological reconstruction. Under these circumstances, PVT has no significant impact on post-LT outcomes[[2](#_ENREF_2)]. Therefore, the portal vein inflow reconstruction pattern, and not the PVT *per se*, determines the efficacy of LT in patients with PVT. Current PVT grading systems, which are mainly based on the location and extent of the thrombus and the degree of occlusion in the vascular lumen, correlate weakly with the adequacy of portal vein inflow after thrombectomy or compensatory collaterals due to the PVT, both of which are crucial for portal vein inflow reconstruction during LT. We aimed in this opinion review to propose a tailored classification of PVT specific for LT, with the primary consideration of strategies for PV inflow reconstruction.

**PREVALENCE OF PVT IN LIVER TRANSPLANT CANDIDATES AND RECIPIENTS**

A large epidemiologic study in northwest Italy identified 3535 new PVT cases from a total population of 13 million over an 11-year period, with an overall incidence of PVT of3.78 and 1.7 per 100000 inhabitants in males and females, respectively[[3](#_ENREF_3)]. However, the prevalence of PVT in liver transplant candidates and recipients is much higher. Analysis of the Organ Procurement and Transplant Network database between 2002 and 2013 showed that PVT was reported in 2819 (3.3%) patients listed for LT and in 3321 (6.8%) patients intraoperatively[[4](#_ENREF_4)]. A Swedish study based on 23796 consecutive autopsies found that 33.1% of 254 PVT cases were associated with cirrhosis and hepatic carcinoma[[5](#_ENREF_5)], the main indications for LT. Specific for LT candidates and recipients, independent risk factors for preoperative PVT include older age, male sex, ethnicity, higher body mass index, longer waitlist time, autoimmune hepatitis, non-alcoholic steatohepatitis, diabetes mellitus, and transjugular intrahepatic portosystemic shunt[[5-8](#_ENREF_5)]. With reference to ethnicity, African Americans had the lowest prevalence of PVT: 2.3% at registration and 4.9% at transplant, whereas Hispanic patients had a significantly higher prevalence: 4.6% at registration and 9.1% at transplant[[6](#_ENREF_6)].

**NATURAL COURSE OF PVT IN CIRRHOSIS**

As a majority of liver transplant candidates and recipients have cirrhosis, it is crucial to obtain insight into the natural course of PVT in cirrhosis. All thromboembolic events can be traced pathophysiologically to the three fundamental components of Virchow’s triads - alterations of normal blood flow, hypercoagulability, and vascular endothelial injury. For PVT in cirrhosis, the first two components are more decisive. Cirrhosis is a chronic process complicated by remodelling of the intrahepatic architecture and portal hemodynamics and by rebalancing of pro- and anticoagulant activities[[9](#_ENREF_9)]. Maruyam *et al*[[10](#_ENREF_10)] performed an excellent study on the natural course of PVT in virus-related cirrhosis, with a rigorous design to exclude almost all interfering factors. None of the enrolled patients received any treatments related to PVT, including anticoagulants, vasoactive drugs, transjugular intrahepatic portosystemic shunt, surgery or even antiviral therapy. Over an 11-year period, *de novo* PVT developed in 28% of 150 patients with virus-related cirrhosis but without PVT at baseline. Moreover, the prevalence of PVT increased along the course of cirrhosis, with cumulative incidences of 12.8%, 20% and 38.7% at 1, 5 and 8-10 years, respectively. The baseline flow volume of the largest collateral vessel was the only independent risk factor for PVT, though collateral vessels were comparably common in the PVT and non-PVT groups, with baseline incidences of 93% and 96%, respectively. Follow-up of the 42 patients with PVT revealed PVT improvement in 47.6%, no change in 45.2%, and worsening in only 7.2%. These findings were consistent with the Organ Procurement and Transplant Network database analysis, which showed that 40% of the listed 1603 patients with PVT did not report PVT at LT[[4](#_ENREF_4)]. Overall, these results are very interesting, indicating that PVT is a multifactor-induced event during the course of cirrhosis but tends to be stable or to resolve.

Portal pressure is a suitable surrogate reflecting remodelling of the intrahepatic architecture and portal hemodynamics. Portal pressure usually increases with the progression of cirrhosis, with a tendency to decrease from its peak value when portal blood flow is partly diverted by collateral vessels. Rebalancing of pro- and anticoagulant activities can be embodied as the intensity of thrombophilia, which increases during the early stage of cirrhosis and decreases during the decompensation period. We believe that the relationship between portal pressure and thrombophilia elucidates the three types of natural courses of PVT: never occurring, occurring but stable or improved, and worsening (Figure 1).

**CURRENT GRADING SYSTEMS FOR PVT**

There are approximately ten grading systems for PVT, as reviewed in two major articles[[1](#_ENREF_1),[11](#_ENREF_11)]. Essentially, these grading systems can be grouped into three categories. The early grading systems only considered the PVT’s location, obstruction and extension, with the Yerdel grading system being the most representative and well recognized[[12](#_ENREF_12)]. The collaterals and cavernous transformation were added in the later grading systems, among which the Jaimeson grading system has been the most instructive[[13](#_ENREF_13)]. The third category of PVT classification involved additional indicators, including duration, presentation and underlying liver disease, and was more complicated[[1](#_ENREF_1),[14](#_ENREF_14)]. Nonetheless, in the setting of LT, these grading systems have limited value because a PVT located in the branches and distal trunk can be resected together with the liver but a more advanced PVT can also be removed through thrombectomy. Cases with insufficient portal blood inflow after thrombectomy and how to use alternative vessels for portal reconstruction are major challenges. Bhangui *et al*[[11](#_ENREF_11)] proposed a dichotomy for PVT, which included complex PVT and noncomplex PVT, grouping Yerdel grade 4 or Jamieson grades 3 and 4 into the former and others into the latter. This classification was used as a guide for portal flow reconstruction during LT, which was also defined by a dichotomy of non-physiological and physiological reconstruction. However, a complex PVT has not always been assigned to a non-physiological reconstruction, and the relationship between a non-complex PVT and physiological reconstruction appears in a same manner.

**TAILORED CLASSIFICATION OF PVT WITH REFERENCE TO PV INFLOW RECONSTRUCTION**

Portal vein inflow reconstruction in LT is a considerable challenge for advanced PVT complicated with structural and hemodynamic abnormalities of the portal venous system, not only with regard to surgical techniques but also with regard to postoperative complications and patient survival. Therefore, PV inflow reconstruction patterns can stratify patients with PVT undergoing liver transplantation. We propose a tailored classification of PVT with reference to three patterns of PV inflow reconstruction, mainly based on the vascular sources providing the portal inflow for the liver graft.

***Type I PVT: Anatomical porto-portal anastomosis with or without devascularization of the collaterals***

Type I PVT is defined as a PVT located in the branches and distal trunk that can definitively be resected with the liver or removed through thrombectomy to recover adequate portal vein blood flow. This type is the most common in LT recipients with PVT. According to a systematic review of the surgical resolution of 1957 patients with PVT,PVT was resected through low dissection of the PV in 5% of the patients and removed through thrombectomy in 75% during LT[[15](#_ENREF_15)]; both conditions would be assigned to type I PVT in our tailored classification, as an end-to-end donor-recipient portal anastomosis was performed thereafter.

Thrombectomy should always be maintained as the first option for any PVT, regardless of location, obstruction and extension; even for Yerdel grade 3 or 4 PVT, thrombectomy can still be performed successfully with appropriate approaches in experienced centres. The key points for thrombectomy include the following: (1) Low dissection of the PV as proximal as possible to reach the superior border of the pancreas; (2) Right operating spaces between the thrombus and the vascular wall; and (3) Appropriate Pringle manipulation with fingers to control bleeding and guide handling. Pan *et al*[[16](#_ENREF_16)] introduced an improved eversion thrombectomy without cutting off the thrombus to obtain persistent traction from the diseased liver through the PVT. Using this technique and simple or eversion thrombectomy, all the Yerdel grade 1 or 2 PVTs in 218 cases were removed successfully, and the success rates for grades 3 and 4 PVT were 79.3% (23/29) and 50% (3/6), respectively. Kasahara *et al*[[17](#_ENREF_17)] and Mizuno *et al*[[18](#_ENREF_18)]also independently reported a pull-out technique for thrombectomy in 6 PVT patients. All inflow branches to the PV above the confluence of the superior mesenteric vein (SMV) and splenic vein (SV) were ligated and transected. The PV trunk was dissected posterior to the pancreas, pulled out inferior to the pancreas, and then transected at the confluence of the SMV and SV. After thrombectomy, the donor PV was placed posterior to the pancreas where the PV was used, and portal reconstruction was performed with or without an interposed vascular graft.

Occasionally, adequate portal vein flow or pressure is not regained even when the PVT is removed completely, probably due to diversion of blood flow by the collaterals. Under these circumstances, devascularization of the collaterals should be considered after restoration of blood inflow to the graft. The dominant collaterals were compensatory enlarged gastric coronary veins and splenorenal shunts, as other collaterals, such as the pericholedochal vascular plexus and umbilical vein, were usually ligated and cut off during resection of the diseased liver, and mesentericocaval shunts in rare cases. The gastric coronary veins are usually easy to deal with in the operative field, though spontaneous or surgical splenorenal shunts are more complicated and require careful evaluation of preoperative images[[19](#_ENREF_19)]. For splenorenal shunts that are difficult to dissect, ligation of the left renal vein might be an alternative strategy that does not affect renal function or recipient survival[[20](#_ENREF_20),[21](#_ENREF_21)]. Diffuse and fine collaterals communicating portal and vena cava systems in the retroperitoneal region, which are common in pediatric recipients, can be thermally devascularized using bipolar electrocoagulators.

***Type II PVT: Veins belonging to the recipient portal system used for portal inflow reconstruction***

Type II PVT is defined as PVT that cannot be removed successfully through thrombectomy to achieve adequate portal vein flow; thus, a substituted inflow vessel is used instead of or in addition to porto-portal anastomosis. The substituted vein belongs to the recipient portal system. Therefore, the reconstruction of portal inflow is still physiological, albeit not anatomical. The main substituted vessels used for patients with type II PVT are mesenteric veins and compensatory enlarged collaterals.

**Recipient mesenteric veins as portal influx:** Vascular graft interposition between recipient mesenteric veins and the donor portal vein was found to be the second most commonly used technique after thrombectomy, accounting for 8.4% of all PVT cases[[15](#_ENREF_15)]. An interposed vascular graft can be an autologous vein such as the external iliac vein, ovarian vein or internal jugular vein, a donor vessel, a cadaveric cryopreserved vessel, or an artificial vessel. The SMV is the main portal influx source because it collects most of the hepatopetal blood from the gut and is closer to the portal vein. The vascular graft interposition has been performed using the jump method, by which the vascular graft is brought to the portahepatis through a transmesocolic route, anterior to the pancreas and posterior to the pyloric antrum. When the SMV distal to its confluence with the splenic vein is not available due to thrombus, hypoplasia or any other reasons, an enlarged inferior mesenteric vein can be used as a portal influx source with a jump vascular graft interposition[[22](#_ENREF_22),[23](#_ENREF_23)].

**Enlarged collaterals as portal influx:** Enlarged collaterals have been used as portal influx in 2.4% of all PVT cases[[15](#_ENREF_15)]. For example, spontaneous splenorenal shunts were the most common collaterals in decompensated cirrhosis patients who underwent evaluation for liver transplantation, with an incidence of 23%[[24](#_ENREF_24)]. Nevertheless, use of the left renal vein to graft PV anastomosis was preferred due to its technical simplification, which is discussed below for the type III PVT. A splenorenal shunt was directly used as portal influx when its confluence to the left renal vein was identified and sectioned, and then the splenorenal shunt was cautiously dissected and brought behind the stomach[[25](#_ENREF_25)]. Among the collaterals, the enlarged left gastric vein or gastric coronary vein was the most commonly used portal influx, as it was superficial, close to the porta hepatis and easy to dissect. Pooled analysis for the left gastric vein or gastric coronary vein as portal influx showed that 92% of 24 patients were alive with a patent portal reconstruction at the last follow-up visit[[11](#_ENREF_11)]. In some cases, a large pericholedochalvarix was the only collateral available for portal reconstruction, but a subsequent Roux-en-Y hepaticojejunostomy was reasonable for biliary reconstruction, as the dissection of recipient bile duct was abandoned beforehand to avoid injury to the pericholedochalvarix[[26](#_ENREF_26),[27](#_ENREF_27)]. Nine of 10 (90%) patients with a pericholedochalvarix as portal influx were reported to be in good condition with a patent portal reconstruction. In case reports, other enlarged mesenteric vein tributaries, such as the right gastroepiploic vein and right and middle colic vein, have been used to reconstruct the portal flow to the graft[[28-32](#_ENREF_28)].

**The splenic vein as portal influx:** Heterotopic liver transplantation in splenic fossa after splenectomy has been proven to be feasible in technique and long-term results[[33](#_ENREF_33),[34](#_ENREF_34)], therefore providing an option for portal reconstruction in PVT patients using the splenic vein. For patients receiving heterotopic liver transplantation in the splenic fossa, the conditions are usually complicated not only by PVT but also by other problems, such as failure to remove the diseased liver. In addition to portal reconstruction, reconstructions for graft outflow, hepatic artery and bile duct are different from orthotopic liver transplantation. Three cases of PVT were reported using heterotopic liver transplantation in the splenic fossa, and two of the patients were in good condition with normal liver function and patent vessels at 60 months and 18 months after the operation[[35](#_ENREF_35),[36](#_ENREF_36)].

***Type III PVT: Vessels that did not belong to the recipient portal system used for portal inflow reconstruction***

In patients with type III PVT, recovered portal inflow to the graft is partly or completely from vessels that do not belong to the recipient portal system, making the portal reconstruction a non-physiological pattern. The strategies for type III PVT include cavoportal hemitransposition (CPHT), renoportal anastomosis, portal vein arterialization and multivisceral transplantation.

**CPHT:** Cavoportal transposition was performed in early animal experiments to determine the effects of portal blood on liver regeneration, as well as the diversion of systemic blood to the liver, and was then used to treat glycogen storage disease clinically in the 1960s[[37](#_ENREF_37)]. CPHT, in which only one anastomosis between the donor PV and recipient inferior vena cava was performed either in an end-to-end or end-to-side way, was first described in liver transplant recipients with diffuse PVT in 1998[[38](#_ENREF_38)]. As a novel and simplified resolution for diffuse PVT, CPHT has been performed in many transplant centres, mainly in the 2000s. However, the results of CPHT were suboptimal and seemed unpredictable. Pooled analysis showed that 63% of 86 patients who underwent CPHT were alive at the last follow-up, but ascites were almost inevitable, with an incidence of portal or cavomesenteric thrombosis of 28% and an incidence of intra-abdominal bleeding of 30%-50%[[11](#_ENREF_11)]. An eventless course after CPHT largely depends on two aspects, namely, proper perfusion to the graft and potential cavoportal shunts. The caval flow directed into the graft should be quick enough to avoid re-thrombosis, but not be too quick to avoid hyperperfusion. Potential cavoportal shunts guarantee the gradual correction of portal hypertension, reducing the risk of intra-abdominal bleeding and refractory ascites. Nonetheless, there is uncertainty in both aspects. Conversely, better results under the same circumstances have been achieved with renoportal anastomosis and multivisceral transplantation. Thus, CPHT has rarely been reported in diffuse PVT in the last decade.

**Renoportal anastomosis (RPA):** RPA was first described in 1997 in a liver transplant recipient with PVT and a surgical splenorenal shunt[[39](#_ENREF_39)]. A total of 64 cases of RPA among PVT patients have been reported[[11](#_ENREF_11),[40-44](#_ENREF_40)]. Among 57 patients with available long-term results, 46 (80.7%) were alive with a patent portal reconstruction at the last follow-up visit; complications related to RPA included ascites (40.4%), renal dysfunction (28.1%), portal thrombosis or stenosis (5.3%) and variceal bleeding (3.5%). The left renal vein was observed to be comparable to the native PV in reference to the vessel size and blood flow. In addition, the proximal left renal vein close to the inferior vena cava was easy to dissect, which ensured the operability of RPA. This technique is particularly reasonable for PVT patients with a pre-existing splenorenal shunt, spontaneous or surgical. RPA drained the splanchnic blood through the splenorenal shunt, effectively decompressing portal hypertension and delivering portal trophic factors to the graft. A major concern for RPA lies in whether it is practicable for diffuse PVT without a splenorenal shunt. To date, 5 cases of RPA in the absence of a splenorenal shunt have been reported; 3 of the patients died, though none of the deaths were directly related to the procedure or complications of RPA. Performing a surgical splenorenal shunt followed by RPA appears to be a solution when RPA is the only option[[11](#_ENREF_11)].

**Portal vein arterialization (PVA):** PVA is more commonly used as a salvage technique when hepatic artery reconstruction is deemed impossible in liver transplantation or hepatopancreatobiliary surgery to increase the oxygen supply to the liver and alleviate ischaemic biliary necrosis[[45](#_ENREF_45)]. This technique was first reported as a solution for portal reconstruction in pre- and post-LT-confirmed PVT in 1995[[46](#_ENREF_46)]. A total of 18 cases of PVA for PVT in liver transplantation have been reported, mainly in the 1990s and 2000s[[46-56](#_ENREF_46)]. In a few of them, PVA was performed to augment portal vein flow after native porto-portal anastomosis but contributed predominantly to portal inflow to the graft over the long term[[52](#_ENREF_52),[55](#_ENREF_55)]. Among the 18 patients, 6 (33.3%) died postoperatively, and 2 underwent embolization of the diverting arteries due to aggravating portal hypertension with related complications. The main drawback of PVA is the impossibility of relieving portal hypertension, which usually leads to an eventful postoperative course. Another disadvantage is overarterialization, which may result in liver fibrosis. Therefore, the arterial flow should be calibrated, by using either medium-sized arterial vessels or partial ligation around the arterial side.

**Multivisceral transplantation (MVT):** MVT, which *en bloc* engrafts the liver, small intestine, stomach, pancreaticoduodenal complex and sometimes a segment of the colon, represents the last surgical option for diffuse PVT, replacing the entire splanchnic venous system of the recipient. Due to the major challenges in this technique, immunosuppression and postoperative management, most MVTs have been performed by a few experienced teams, though there has been tremendous progress over the past decades[[57-60](#_ENREF_57)]. The first case of successful MVT for diffuse portomesenteric thrombosis, which resulted from protein C deficiency, was reported in 2002[[61](#_ENREF_61)]. The Indiana group reported 34 cases, the largest single-centre series of MVT for diffuse PVT, and patient survival was 80% at 1 year and 72% at 3 and 5 years postoperatively, with a median follow-up of 2.78 years[[58](#_ENREF_58),[62](#_ENREF_62)]. However, surgical complications occurred in 56% of the patients. The steep learning curve and additional risks of the intestinal component of MVT, such as rejection, sepsis, malnourishment and post-transplant lymphoproliferative disorder, remain major obstacles for the routine adoption of MVT in diffuse PVT.

**ROLES OF THE TAILORED PVT CLASSIFICATION IN THE SETTING OF LIVER TRANSPLANTATION**

Type I, II, and III PVTs strictly correspond to three patterns of PV inflow reconstruction in LT: anatomical, physiological, and non-physiological reconstruction. This tailored classification can stratify PVT patients by surgical complexity and risk of postoperative complications, as well as long-term survival. Although it is not a preoperative classification, the PVT type can be predicted before liver transplantation through rigorous evaluations via abdominal CT angiography and symptoms of portal hypertension. A proposed algorithm for the tailored PVT classification and PV reconstruction strategy is illustrated in Figure 2.

We advocate using this tailored classification for PVT grading before LT, even though the determined type may change during the operation. The tailored PVT classification allows for better preoperative planning, urging transplant surgeons to pay more attention to all potential strategies for portal reconstruction. In addition to the conditions of the recipients, the procurement of donor organs and interposed vascular grafts, as well as the technical capacity of MVT, should be fully considered. Only in this way can portal reconstruction be performed as planned rather than passively. Furthermore, a large-sample retrospective study should be performed with regard to the development of a model to accurately predict the tailored PVT type before LT, which should be verified in an independent cohort.

**REFERENCES**

1 **Sarin SK**, Philips CA, Kamath PS, Choudhury A, Maruyama H, Nery FG, Valla DC. Toward a Comprehensive New Classification of Portal Vein Thrombosis in Patients With Cirrhosis. *Gastroenterology* 2016; **151**: 574-577 [PMID: 27575821 DOI: 10.1053/j.gastro.2016.08.033]

2 **Intagliata NM**, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. *Gastroenterology* 2019; **156**: 1582-1599 [PMID: 30771355 DOI: 10.1053/j.gastro.2019.01.265]

3 **Ageno W**, Dentali F, Pomero F, Fenoglio L, Squizzato A, Pagani G, Re R, Bonzini M. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. *ThrombHaemost* 2017; **117**: 794-800 [PMID: 28180235 DOI: 10.1160/TH16-10-0781]

4 **Ghabril M**, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ. Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients. *Transplantation* 2016; **100**: 126-133 [PMID: 26050013 DOI: 10.1097/TP.0000000000000785]

5 **Ogren M**, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. *World J Gastroenterol* 2006; **12**: 2115-2119 [PMID: 16610067 DOI: 10.3748/wjg.v12.i13.2115]

6 **Bezinover D**, Reeder E, Aziz F, Saner F, McQuillan P, Kadry Z, Riley T, Guvakov D, Janicki PK. African Americans have a lower prevalence of portal vein thrombosis at the time of liver transplantation. *HPB (Oxford)* 2017; **19**: 620-628 [PMID: 28495438 DOI: 10.1016/j.hpb.2017.04.002]

7 **Bezinover D**, Iskandarani K, Chinchilli V, McQuillan P, Saner F, Kadry Z, Riley TR, Janicki PK. Autoimmune conditions are associated with perioperative thrombotic complications in liver transplant recipients: A UNOS database analysis. *BMC Anesthesiol* 2016; **16**: 26 [PMID: 27207434 DOI: 10.1186/s12871-016-0192-3]

8 **Stine JG**, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. *Liver Transpl* 2015; **21**: 1016-1021 [PMID: 25845711 DOI: 10.1002/lt.24134]

9 **Tripodi A**, Mannucci PM. The coagulopathy of chronic liver disease. *N Engl J Med* 2011; **365**: 147-156 [PMID: 21751907 DOI: 10.1056/NEJMra1011170]

10 **Maruyama H**, Okugawa H, Takahashi M, Yokosuka O. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. *Am J Gastroenterol* 2013; **108**: 568-574 [PMID: 23381015 DOI: 10.1038/ajg.2012.452]

11 **Bhangui P**, Lim C, Levesque E, Salloum C, Lahat E, Feray C, Azoulay D. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation. *J Hepatol* 2019; **71**: 1038-1050 [PMID: 31442476 DOI: 10.1016/j.jhep.2019.08.012]

12 **Yerdel MA**, Gunson B, Mirza D, Karayalçin K, Olliff S, Buckels J, Mayer D, McMaster P, Pirenne J. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. *Transplantation* 2000; **69**: 1873-1881 [PMID: 10830225DOI:10.1097/00007890-200005150-00023]

13 **Jamieson NV**. Changing perspectives in portal vein thrombosis and liver transplantation. *Transplantation* 2000; **69**: 1772-1774 [PMID: 10830208 DOI: 10.1097/00007890-200005150-00006]

14 **de Franchis R**; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; **63**: 743-752 [PMID: 26047908 DOI: 10.1016/j.jhep.2015.05.022]

15 **Rodríguez-Castro KI**, Porte RJ, Nadal E, Germani G, Burra P, Senzolo M. Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. *Transplantation* 2012; **94**: 1145-1153 [PMID: 23128996 DOI: 10.1097/TP.0b013e31826e8e53]

16 **Pan C**, Shi Y, Zhang JJ, Deng YL, Zheng H, Zhu ZJ, Shen ZY. Single-center experience of 253 portal vein thrombosis patients undergoing liver transplantation in China. *Transplant Proc* 2009; **41**: 3761-3765 [PMID: 19917382 DOI: 10.1016/j.transproceed.2009.06.215]

17 **Kasahara M**, Sasaki K, Uchida H, Hirata Y, Takeda M, Fukuda A, Sakamoto S. Novel technique for pediatric living donor liver transplantation in patients with portal vein obstruction: The "pullout technique". *Pediatr Transplant* 2018; **22**: e13297 [PMID: 30280455 DOI: 10.1111/petr.13297]

18 **Mizuno S**, Murata Y, Kuriyama N, Ohsawa I, Kishiwada M, Hamada T, Usui M, Sakurai H, Tabata M, Isaji S. Living donor liver transplantation for the patients with portal vein thrombosis: use of an interpositional venous graft passed posteriorly to the pancreatic parenchyma without using jump graft. *Transplant Proc* 2012; **44**: 356-359 [PMID: 22410015 DOI: 10.1016/j.transproceed.2012.01.039]

19 **Kim H**, Yoon KC, Lee KW, Yi NJ, Lee HW, Choi Y, Oh D, Kim HS, Hong SK, Ahn SW, Suh KS. Tips and pitfalls in direct ligation of large spontaneous splenorenal shunt during liver transplantation. *Liver Transpl* 2017; **23**: 899-906 [PMID: 28481004 DOI: 10.1002/lt.24783]

20 **Nguyen MC**, Sage Silski L, Alebrahim M, Black S, Elkhammas E, Washburn K, El-Hinnawi A. Left Renal Vein Ligation for Spontaneous Splenorenal Shunts During Deceased-Donor Orthotopic Liver Transplant Is Safe and Can Mitigate Complications from Portal Steal: A Case Series. *Exp Clin Transplant* 2018 [PMID: 30501587 DOI: 10.6002/ect.2018.0096]

21 **Golse N**, Bucur PO, Faitot F, Bekheit M, Pittau G, Ciacio O, Sa Cunha A, Adam R, Castaing D, Samuel D, Cherqui D, Vibert E. Spontaneous Splenorenal Shunt in Liver Transplantation: Results of Left Renal Vein Ligation Versus Renoportal Anastomosis. *Transplantation* 2015; **99**: 2576-2585 [PMID: 25989502 DOI: 10.1097/TP.0000000000000766]

22 **Puri Y**, Gunasekaran V, Palanisamy SK, Elangovan B, Krishna P, Balasubramanian B, Ananth A, Reddy MS, Rela M. A Novel Technique of Physiological Portal Inflow Augmentation During Liver Transplantation for Yerdel Grade 4 Portal Vein Thrombosis. *Liver Transpl* 2020; **26**: 294-298 [PMID: 31724287 DOI: 10.1002/lt.25680]

23 **Hwang HP**, Yang JD, Bae SI, Hwang SE, Cho BH, Yu HC. Usefulness of artificial jump graft to portal vein thrombosis in deceased donor liver transplantation. *Yonsei Med J* 2015; **56**: 586-590 [PMID: 25684014 DOI: 10.3349/ymj.2015.56.2.586]

24 **Saks K**, Jensen KK, McLouth J, Hum J, Ahn J, Zaman A, Chang MF, Fung A, Schlansky B. Influence of spontaneous splenorenal shunts on clinical outcomes in decompensated cirrhosis and after liver transplantation. *HepatolCommun* 2018; **2**: 437-444 [PMID: 29619421 DOI: 10.1002/hep4.1157]

25 **Manzia TM**, Fazzolari L, Manuelli M, Pellicciaro M, Baiocchi L, Tisone G. Liver transplantation in a patient with complete portal vein thrombosis, is there a surgical way out? A case report.*Ann Med Surg (Lond)* 2016; **11**: 5-8 [PMID: 27625785 DOI: 10.1016/j.amsu.2016.08.002]

26 **Bharathy KG**, Sasturkar SV, Sinha PK, Kumar S, Pamecha V. Portal Inflow in Extensive Portomesenteric Thrombosis: Using the PericholedochalVarix in Living Donor Liver Transplantation. *J Clin Exp Hepatol* 2017; **7**: 63-65 [PMID: 28348472 DOI: 10.1016/j.jceh.2016.10.007]

27 **Yu YD**, Kim DS, Han JH, Yoon YI. Successful Treatment of a Patient With Diffuse Portosplenomesenteric Thrombosis Using a PericholedochalVarix for Portal Flow Reconstruction During Deceased Donor Liver Transplantation: A Case Report. *Transplant Proc* 2017; **49**: 1202-1206 [PMID: 28583558 DOI: 10.1016/j.transproceed.2017.03.066]

28 **Pinheiro RS**, Cruz RJ Jr, Nacif LS, Vane MF, D'Albuquerque LA. Successful liver allograft inflow reconstruction with the right gastroepiploic vein. *HepatobiliaryPancreat Dis Int* 2016; **15**: 106-107 [PMID: 26818551 DOI: 10.1016/s1499-3872(15)60369-1]

29 **Davidson BR**, Gibson M, Dick R, Burroughs A, Rolles K. Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. *Transplantation* 1994; **57**: 1174-1177 [PMID: 8178342 DOI: 10.1097/00007890-199404270-00006]

30 **Langnas AN**, Marujo WC, Stratta RJ, Wood RP, Ranjan D, Ozaki C, Shaw BW Jr. A selective approach to preexisting portal vein thrombosis in patients undergoing liver transplantation. *Am J Surg* 1992; **163**: 132-136 [PMID: 1733361 DOI: 10.1016/0002-9610(92)90265-s]

31 **Magistri P**, Tarantino G, Olivieri T, Pecchi A, Ballarin R, Di Benedetto F. Extra-Anatomic Jump Graft from the Right Colic Vein: A Novel Technique to Manage Portal Vein Thrombosis in Liver Transplantation. *Case Rep Surg* 2018; **2018**: 4671828 [PMID: 29593928 DOI: 10.1155/2018/4671828]

32 **Rudroff C**, Scheele J. The middle colic vein: an alternative source of portal inflow in orthotopic liver transplantation complicated by portal vein thrombosis. *Clin Transplant* 1998; **12**: 538-542 [PMID: 9850447]

33 **Zhang G**, Zhu Y, Qin W, Yu L, Wu G, Ma S, Wang F, Qin R, Yang X, Tao K, Yue S, Zhao G, Yang Z, Yuan J, Dou K, Yuan J. Combined Kidney Transplantation and Splenic Fossa Auxiliary Heterotopic Liver Transplantation in a Highly Sensitized Recipient: A Case Report. *Transplant Proc* 2016; **48**: 3191-3196 [PMID: 27932179 DOI: 10.1016/j.transproceed.2016.09.007]

34**Dou K**, Wang D, Tao K, Yue S, Ti Z, Song Z, Li L, He Y, Hou X. A modified heterotopic auxiliary living donor liver transplantation: report of a case. *Ann Hepatol* 2014; **13**: 399-403 [PMID: 24756018DOI:10.1016/S1665-2681(19)30872-5]

35 **Azoulay D**, Lahat E, Salloum C, Compagnon P, Feray C. Heterotopic liver retransplantation for impossible former graft explantation. *Hepatology* 2017; **66**: 655-657 [PMID: 28120420 DOI: 10.1002/hep.29077]

36 **Muscari F**, Suc B, Fourtanier G, Escat J. [Liver transplantation in the presence of a non-functional portal vein: an original technique]. *Ann Chir* 2001; **126**: 111-117 [PMID: 11284100 DOI: 10.1016/s0003-3944(00)00473-9]

37 **Starzl TE**, Marchioro TL, Sexton AW, Illingworth B, Waddell WR, Faris TD, Herrmann TJ. The effect of portacaval transposition on carbohydrate metabolism: Experimental and clinical observations. *Surgery* 1965; **57**: 687-697 [PMID: 14295780]

38 **Tzakis AG**, Kirkegaard P, Pinna AD, Jovine E, Misiakos EP, Maziotti A, Dodson F, Khan F, Nery J, Rasmussen A, Fung JJ, Demetris A, Ruiz PJ. Liver transplantation with cavoportalhemitransposition in the presence of diffuse portal vein thrombosis. *Transplantation* 1998; **65**: 619-624 [PMID: 9521194DOI:10.1097/00007890-199803150-00004]

39 **Sheil AG**, Stephen MS, Chui AK, Ling J, Bookallil MJ. A liver transplantation technique in a patient with a thrombosed portal vein and a functioning renal-lieno shunt. *Clin Transplant* 1997; **11**: 71-73 [PMID: 9067699]

40 **D'Amico G**, Hassan A, DiagoUso T, Hashmimoto K, Aucejo FN, Fujiki M, Eghtesad B, Sasaki K, Lindenmeyer CC, Miller CM, Quintini C. Renoportal anastomosis in liver transplantation and its impact on patient outcomes: a systematic literature review. *TransplInt* 2019; **32**: 117-127 [PMID: 30362294 DOI: 10.1111/tri.13368]

41 **Neto JS**, Fonseca EA, Cândido HL, Pugliese R, Feier FH, Kondo M, Azambuja RL, Chapchap P. Alternatives for vascular reconstruction in pediatric living donor liver transplantation. *Pediatr Transplant* 2016; **20**: 717-722 [PMID: 27174167 DOI: 10.1111/petr.12720]

42 **Mori A**, Iida T, Iwasaki J, Ogawa K, Fujimoto Y, Uemura T, Hatano E, Okajima H, Kaido T, Uemoto S. Portal vein reconstruction in adult living donor liver transplantation for patients with portal vein thrombosis in single center experience. *J HepatobiliaryPancreatSci* 2015; **22**: 467-474 [PMID: 25755116 DOI: 10.1002/jhbp.235]

43 **Ogasawara H**, Nakanishi C, Miyagi S, Tokodai K, Hara Y, Nakanishi W, Miyazawa K, Shimizu K, Kumata H, Goto H, Goto M, Unno M, Kamei T. Renoportal Anastomosis in Left Lateral Lobe Living Donor Liver Transplantation: A Pediatric Case. *Case Rep Gastroenterol* 2017; **11**: 584-592 [PMID: 29118687 DOI: 10.1159/000481160]

44 **Miyamoto A**, Kato T, Dono K, Umeshita K, Kawabata R, Hayashi S, Kubota M, Kobayashi S, Nagano H, Nakamori S, Sakon M, Monden M. Living-related liver transplantation with renoportal anastomosis for a patient with large spontaneous splenorenal collateral. *Transplantation* 2003; **75**: 1596-1598 [PMID: 12792522 DOI: 10.1097/01.TP.0000061769.78127.5D]

45 **Bhangui P**, Salloum C, Lim C, Andreani P, Ariche A, Adam R, Castaing D, Kerba T, Azoulay D. Portal vein arterialization: a salvage procedure for a totally de-arterialized liver. The Paul Brousse Hospital experience. *HPB (Oxford)* 2014; **16**: 723-738 [PMID: 24329988 DOI: 10.1111/hpb.12200]

46 **Erhard J**, Lange R, Giebler R, Rauen U, de Groot H, Eigler FW. Arterialization of the portal vein in orthotopic and auxiliary liver transplantation. A report of three cases. *Transplantation* 1995; **60**: 877-879 [PMID: 7482751DOI:10.1097/00007890-199510000-00020]

47 **Neelamekam TK**, Geoghegan JG, Curry M, Hegarty JE, Traynor O, McEntee GP. Delayed correction of portal hypertension after portal vein conduit arterialization in liver transplantation. *Transplantation* 1997; **63**: 1029-1030 [PMID: 9112360 DOI: 10.1097/00007890-199704150-00022]

48 **Settmacher U**, Stange B, Schaser KD, Puhl G, Glanemann M, Steinmüller T, Heise M, Neuhaus P. Primary permanent arterialization of the portal vein in liver transplantation. *TransplInt* 2003; **16**: 430-433 [PMID: 12819875 DOI: 10.1007/s00147-003-0565-7]

49 **Charco R**, Margarit C, López-Talavera JC, Hidalgo E, Castells L, Allende H, Segarra A, Moreíras M, Bilbao I. Outcome and hepatic hemodynamics in liver transplant patients with portal vein arterialization. *Am J Transplant* 2001; **1**: 146-151 [PMID: 12099362DOI:10.1034/j.1600-6143.2001.10208.x]

50 **Ott R**, Böhner C, Müller S, Aigner T, Bussenius-Kammerer M, Yedibela S, Kissler H, Hohenberger W, Reck T, Müller V. Outcome of patients with pre-existing portal vein thrombosis undergoing arterialization of the portal vein during liver transplantation. *TransplInt* 2003; **16**: 15-20 [PMID: 12545336 DOI: 10.1007/s00147-002-0505-y]

51 **Nivatvongs S**, Sirijindakul B, Nontasoot B. Portal vein arterialization for liver transplantation with extensive portomesenteric vein thrombosis: a case report. *Transplant Proc* 2004; **36**: 2267-2268 [PMID: 15561214 DOI: 10.1016/j.transproceed.2004.07.073]

52 **Bonnet S**, Sauvanet A, Bruno O, Sommacale D, Francoz C, Dondero F, Durand F, Belghiti J. Long-term survival after portal vein arterialization for portal vein thrombosis in orthotopic liver transplantation. *Gastroenterol Clin Biol* 2010; **34**: 23-28 [PMID: 19643558 DOI: 10.1016/j.gcb.2009.05.013]

53 **Aspinall RJ**, Seery JP, Taylor-Robinson SD, Habib N. Comments on "arterialization of the portal vein in orthotopic and auxiliary liver transplantation". *Transplantation* 1996; **62**: 1375-1376 [PMID: 8932292 DOI: 10.1097/00007890-199611150-00038]

54 **Stange B**, Glanemann M, Nüssler NC, Bechstein WO, Neuhaus P, Settmacher U. Indication, technique, and outcome of portal vein arterialization in orthotopic liver transplantation. *Transplant Proc* 2001; **33**: 1414-1415 [PMID: 11267352 DOI: 10.1016/s0041-1345(00)02533-1]

55 **Paloyo S**, Nishida S, Fan J, Tekin A, Selvaggi G, Levi D, Tzakis A. Portal vein arterialization using an accessory right hepatic artery in liver transplantation. *Liver Transpl* 2013; **19**: 773-775 [PMID: 23554089 DOI: 10.1002/lt.23653]

56 **Zhang K**, Jiang Y, Lv LZ, Cai QC, Yang F, Hu HZ, Zhang XJ. Portal vein arterialization technique for liver transplantation patients. *World J Gastroenterol* 2014; **20**: 12359-12362 [PMID: 25232274 DOI: 10.3748/wjg.v20.i34.12359]

57 **Tzakis AG**, Kato T, Levi DM, Defaria W, Selvaggi G, Weppler D, Nishida S, Moon J, Madariaga JR, David AI, Gaynor JJ, Thompson J, Hernandez E, Martinez E, Cantwell GP, Augenstein JS, Gyamfi A, Pretto EA, Dowdy L, Tryphonopoulos P, Ruiz P. 100 multivisceral transplants at a single center. *Ann Surg* 2005; **242**: 480-490; discussion 491-493 [PMID: 16192808 DOI: 10.1097/01.sla.0000183347.61361.7a]

58 **Mangus RS**, Tector AJ, Kubal CA, Fridell JA, Vianna RM. Multivisceral transplantation: expanding indications and improving outcomes. *J GastrointestSurg* 2013; **17**: 179-186; discussion186-187 [PMID: 23070622 DOI: 10.1007/s11605-012-2047-7]

59 **Abu-Elmagd KM**, Costa G, Bond GJ, Soltys K, Sindhi R, Wu T, Koritsky DA, Schuster B, Martin L, Cruz RJ, Murase N, Zeevi A, Irish W, Ayyash MO, Matarese L, Humar A, Mazariegos G. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. *Ann Surg* 2009; **250**: 567-581 [PMID: 19730240 DOI: 10.1097/SLA.0b013e3181b67725]

60 **Grant D**, Abu-Elmagd K, Mazariegos G, Vianna R, Langnas A, Mangus R, Farmer DG, Lacaille F, Iyer K, Fishbein T; Intestinal Transplant Association. Intestinal transplant registry report: global activity and trends. *Am J Transplant* 2015; **15**: 210-219 [PMID: 25438622 DOI: 10.1111/ajt.12979]

61 **Florman SS**, Fishbein TM, Schiano T, Letizia A, Fennelly E, DeSancho M. Multivisceral transplantation for portal hypertension and diffuse mesenteric thrombosis caused by protein C deficiency. *Transplantation* 2002; **74**: 406-407 [PMID: 12177622 DOI: 10.1097/00007890-200208150-00019]

62 **Vianna RM**, Mangus RS, Kubal C, Fridell JA, Beduschi T, Tector AJ. Multivisceral transplantation for diffuse portomesenteric thrombosis. *Ann Surg* 2012; **255**: 1144-1150 [PMID: 22549750 DOI: 10.1097/SLA.0b013e31825429c0]

**Footnotes**

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support was provided.

**Open-Access:**This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** February17, 2020

**First decision:** March15, 2020

**Article in press:** April 22, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D(Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Chiu KW, SandowSL, SlomianyBL, **S-Editor:** Wang J **L-Editor:** MedE-Ma JY **E-Editor:** Ma YJ

**Figure Legends**



**Figure 1 Relationship between portal pressure and thrombophilia in the natural course of portal vein thrombosis.** A: Portal pressure increases gradually, while the intensity of thrombophilia increases and then decreases. No crossover of the two curves means that portal vein thrombosis (PVT) never occurs; B: The two curves cross each other, but portal pressure continues to increase, and its curve is separate from the curve of thrombophilia; thus, PVT occurs but stabilizes or improves; C: Portal pressure increases at first and then decreases due to diversion of the blood flow by the collaterals. The two curves cross and remain close to each other, meaning that PVT occurs and worsens.



**Figure 2 A proposed algorithm for the tailored portal vein thrombosis classification and portal vein reconstruction strategy.** CPHT: Cavoportal hemitransposition; MVT: Multivisceral transplantation; PV: Portal vein; PVA: Portal vein arterialization; RPA: Renoportal anastomosis; SMV: Superior mesenteric vein; SV: Splenic vein.